Clinical trial evaluating AN9025 for RAS-mutated solid tumors initiated
A clinical trial is underway to assess the safety and tolerability of AN9025 in patients with RAS-mutated solid tumors.
Therapeutic Area
Therapeutic area intelligence for RAS Inhibitor with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.